Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Summary

Cardiovascular disease is a major public health problem in our country. Among the causes of cardiovascular diseases are High Blood Pressure (HBP) and Diabetes Mellitus (DM). Type 2 diabetes (DM2) is associated with a twofold risk of cardiovascular disease, and endothelial dysfunction is an early marker of vascular complications. There is evidence of action of glucagon-like peptide 1 (GLP-1) on endothelial cells and vascular smooth muscle. Vildagliptin is a drug used in the treatment of DM2 able to prolong the activity of GLP-1, improving glycemic control and endothelial function. Objectives: To evaluate the effect of vildagliptin on endothelial function in patients with DM2 and hypertension using the Endo-PAT 2000 device.

Timeline

Start

2013-07

Primary completion

2016-05

Completion

2016-05

Publications

• Cosenso-Martin LN, Giollo-Junior LT, Fernandes LAB, Cesarino CB, Nakazone MA, Machado MN, Yugar-Toledo JC, Vilela-Martin JF. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Acta Diabetol. 2018 Dec;55(12):1237-1245. doi: 10.1007/s00592-018-1204-1. Epub 2018 Aug 9.
• Cosenso-Martin LN, Giollo-Junior LT, Martineli DD, Cesarino CB, Nakazone MA, Cipullo JP, Vilela-Martin JF. Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr. 2015 Aug 26;7:70. doi: 10.1186/s13098-015-0062-z. eCollection 2015.

Drugs

Indications